

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31ST DECEMBER, 2008

(Rs.in Lakhs)

	Particulars	STANDALONE					CONSOLIDATED				
		Quarter ended 31.12.2008	Quarter Ended 31.12.2007	9-Months ended 31.12.2008	9-Months ended 31.12.2007	Year ended 31.03.2008	Quarter ended 31.12.2008	Quarter ended 31.12.2007	9-Months ended 31.12.2008	9-Months ended 31.12.2007	Year ended 31.03.2008
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	26742	28422	86471	75480	103319	26475	28413	85880	75469	103283
	(b) Other Operating Income	475	277	1084	717	1174	475	277	1084	718	1231
	Total Income	27217	28699	87555	76197	104493	26950	28690	86964	76187	104514
2	<u>Expenditure:</u>										
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	(4345)	473	(11166)	(2268)	(3219)	(4773)	442	(12409)	(2461)	(3569)
	b. Consumption of Raw Material	14747	11664	41890	33260	44388	14696	11675	41955	33310	44528
	c. Purchase of Traded Goods	0	0	0	0	0	0	0	0	0	0
	d. Staff Cost	1585	1237	4664	3597	5054	1704	1351	4981	3926	5419
	e. Depreciation	1228	906	3494	2549	3565	1228	907	3496	2551	3568
	f. Other Expenditure										
	- Manufacturing Expenses	1975	1805	5681	4880	6451	1976	1806	5792	4993	6561
	- Other expenses	3054	1888	8650	5729	8954	3447	1968	9601	5921	9386
	g. Total	18244	17973	53213	47747	65193	18278	18149	53416	48240	65893
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	8973	10726	34342	28450	39300	8672	10541	33548	27947	38621
4	Other Income	312	28	738	86	187	292	18	688	58	148
5	Profit before Interest & Exceptional Items (3+4)	9285	10754	35080	28536	39487	8964	10559	34236	28005	38769
6	Interest/Finance Charges	162	183	541	835	1018	162	183	542	836	1019
7	Profit after Interest but before Exceptional Items (5-6)	9123	10571	34539	27701	38469	8802	10376	33694	27169	37750
8	Exceptional items	0	0	0	0	0	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax</u> (7+8)	9123	10571	34539	27701	38469	8802	10376	33694	27169	37750

10	Tax Expense										
	- Current Tax	615	1109	2632	2960	3834	615	1109	2632	2960	3834
	- MAT Credit Entitlements	(28)	(502)	(523)	(1863)	(1930)	(28)	(502)	(523)	(1863)	(1930)
	- Deferred Tax	291	(112)	757	666	1177	259	(147)	645	561	1054
	- Fringe Benefit Tax	3	10	15	19	32	3	10	15	19	32
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	8242	10066	31658	25919	35356	7953	9906	30925	25492	34760
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	8242	10066	31658	25919	35356	7953	9906	30925	25492	34760
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	1295	1291	1295	1291	1291	1295	1291	1295	1291	1291
15	Reserves excluding revaluation reserves					86107					84849
16	Earnings per Share										
a)	Basic Earnings Per Share before extra-ordinary items Rs.	12.73	15.59	48.92	40.15	54.77	12.29	15.35	47.79	39.49	53.84
	Diluted Earnings Per Share before extra-ordinary items Rs.	12.61	15.41	48.42	39.69	54.14	12.16	15.17	47.30	39.03	53.23
b)	Basic Earnings Per Share after extra-ordinary items Rs.	12.73	15.59	48.92	40.15	54.77	12.29	15.35	47.79	39.49	53.84
	Diluted Earnings Per Share after extra-ordinary items Rs.	12.61	15.41	48.42	39.69	54.14	12.16	15.17	47.30	39.03	53.23
17	Public shareholding:										
	- No. of shares	30164225	29992600	30164225	29992600	29972600	30164225	29992600	30164225	29992600	29972600
	- % of shareholding	46.59%	46.46%	46.59%	46.46%	46.43%	46.59%	46.46%	46.59%	46.46%	46.43%

NOTES:

1. The above results for the Quarter and Nine months period ended 31st December 2008, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 24th January, 2009.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting notified under the Companies Act, 1956.
3. The consolidated results include the unaudited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG
4. The figures for the previous year/period have been reclassified/regrouped, wherever necessary.
5. During the current quarter, the company has allotted 24,400 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 31.12.2008:
Opening: Nil, Received during the Quarter: 27, Resolved: 27, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 24-01-2009

Dr. Murali K. Divi
Chairman & Managing Director